|
| |
Neurotech Names Ted Danse as New President
and CEO
Lincoln, RI and Paris, France,
October 13, 2005 – Neurotech, a biotechnology company specializing in the
development of sight-saving innovative therapeutics for chronic retinal
diseases, announced today the appointment of Ted Danse as its new President and
Chief Executive Officer.
Mr. Danse has over 25 years of life science experience, including more than 20
years in the ophthalmic industry. Previously he served as President and CEO of
the US ophthalmic pharmaceutical company ISTA Pharmaceuticals Inc. where he was
responsible for taking the company public in 2000. He has also served as a
Director on the boards of two development-stage ophthalmic companies, Quest
Vision Technologies, Inc. and Vision Solutions Technologies, Inc. His early
career was spent in business development roles at Coopervision, Bausch & Lomb
and Schering-Plough. He then went on to hold various senior positions in
Allergan. Mr. Danse holds a BA degree from the University of the Pacific,
California, USA and an MBA from Thunderbird, The Garvin Graduate School of
International Management, Arizona, USA.
“I am stepping into this pivotal position at Neurotech with great anticipation;
it is a very exciting time for the development of the company,” commented Mr.
Danse, “Using my experiences at ISTA, Allergan and other US ophthalmic
companies, I will bring a vital new perspective to the growth of Neurotech.”
“We are delighted to have someone of Ted’s calibre join us in the CEO role of
Neurotech at a time when the company is poised to advance significantly with its
technology,” stated Dr. Laurent Ganem, Partner of Apax Partners, a Director and
leading shareholder of Neurotech.
Mark Clement, Chief Executive of Merlin Biosciences Limited, a Director and
leading shareholder of Neurotech, added, “Ted brings to the Neurotech team many
years of experience in some of the leading companies in our sector. We are sure
he will lead the company to the forefront of the ophthalmic industry.”
Mr. Danse will be based at the company’s U.S. headquarters in Lincoln, Rhode
Island.
About Neurotech
Neurotech is a biotechnology company dedicated to the development of
sight-saving therapeutics for chronic retinal diseases. Retinal diseases
represent significant unmet medical needs for which new medical therapies are
the largest market opportunity in ophthalmology. Neurotech’s lead product
(NT-501) is in clinical development for the treatment of retinal degeneration,
including retinitis pigmentosa, an inherited disease leading to blindness,
geographic atrophy, a serious condition associated with atrophic (dry) macular
degeneration, and is evaluating other factors that can be used with its
proprietary delivery technology to treat additional retinal diseases. The
company’s U.S. office is headquartered in Lincoln, RI, and European operations
are located in Paris. Neurotech is supported in its scientific and business
strategies by world experts in ophthalmology and by a group of international
investors led by Apax Partners and Merlin Biosciences.
To learn more about Neurotech, please visit our web site at
www.neurotechusa.com
###
Contacts:
Corporate:
Neurotech
Ted Danse
President and CEO
401 333-3880
Media Relations: Europe
Douglas Pretsell
Northbank Communications
d.pretsell@northbankcommunications.com
+49 (0)89 570 018 06
Investor Relations: USA
Lisa Burns
Burns McClellan Inc.
lburns@burnsmc.com
212 216-0006
Media Relations: USA
Carney Duntsch
Burns McClellan Inc.
cduntsch@burnsmc.com
212 213-0006
| |
|
